Scarica l'app Stockscreener
9.93
7.35%
0.68
Pre-mercato:
9.96
0.03
+0.30%
Precedente Chiudi:
$9.25
Aprire:
$9.33
Volume 24 ore:
627.44K
Relative Volume:
0.63
Capitalizzazione di mercato:
$442.48M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+8.05%
1M Prestazione:
+32.75%
6M Prestazione:
-59.89%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.2804
$10.23
Intervallo di 1 settimana:
$9.1101
$10.23
Portata 52W:
$4.17
$28.99
Septerna Inc Stock (SEPN) Company Profile
Nome
Septerna Inc
Settore
Industria
Telefono
650-338-3533
Indirizzo
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Confronta SEPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
9.93 | 429.99M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-19 | Iniziato | JP Morgan | Overweight |
| 2024-11-19 | Iniziato | TD Cowen | Buy |
| 2024-11-19 | Iniziato | Wells Fargo | Overweight |
Septerna Inc Borsa (SEPN) Ultime notizie
Septerna To Present At Jefferies Conference; SEP-631 Phase 1 Trial On Track For Q3 - Nasdaq
Septerna to Present at Jefferies Global Healthcare Conference - TradingView
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - Bilyonaryo Business News
Jane Street Group LLC Invests $600,000 in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Analysts Think These Stocks Could More Than Double in Value - Investing.com
Analysts Think These Stocks Could More Than Double in Value - MarketBeat
Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect? - MSN
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled - MSN
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - The Globe and Mail
Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal - MSN
Cantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN) - The Globe and Mail
Wells Fargo & Company Boosts Septerna (NASDAQ:SEPN) Price Target to $18.00 - Defense World
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies - MSN
Septerna First Quarter 2025 Earnings: US$0.49 loss per share (vs US$6.35 loss in 1Q 2024) - simplywall.st
22,095 Shares in Septerna, Inc. (NASDAQ:SEPN) Bought by The Manufacturers Life Insurance Company - Defense World
ETFs to Capitalize on the Novo Nordisk-Septerna Deal - MSN
Novo Nordisk in pact with Septerna for oral obesity drugs - MSN
Septerna: Novo's Investment In Incretin Program IntriguesOne For The Watchlist - Seeking Alpha
Where Septerna Stands With Analysts - Benzinga
Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash - Seeking Alpha
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight By Investing.com - Investing.com Nigeria
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight - Investing.com
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership - PMLiVE
Septerna price target raised to $18 from $11 at Wells Fargo - TipRanks
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills - MSN
Biotech Stocks Worth Watching – May 14th - Defense World
Novo Nordisk (NVO) Deal Highlights Strategic Potential Amid Septerna Developments | NVO Stock News - GuruFocus
Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating - TipRanks
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna - MSN
Septerna reports Q1 EPS (49c), consensus (45c) - TipRanks
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - The Manila Times
Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs - Contract Pharma
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk - MSN
Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments - MSN
Novo Nordisk, Septerna collaborate on developing GPCR therapies - World Pharmaceutical Frontiers
Novo Nordisk Partners with Septerna for New Obesity Drug Development - GuruFocus
Novo Nordisk, Septerna Ink Up To $2.2B Obesity Drug Deal - Law360
Novo Nordisk Looks To Septerna For Oral Obesity Options - insights.citeline.com
Septerna joins a $2.2B obesity deal with Novo - BioWorld MedTech
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily
eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal - Yahoo Finance
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside | FinancialContent - FinancialContent
This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent - MSN
Septerna Stock Spikes on Novo Nordisk Obesity Drug Deal - Wall Street Pit
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B - BioSpace
Peninsula biotech Septerna lands deal for oral GLP-1 weight-loss drugs, stock zooms higher - The Business Journals
Novo Nordisk (NVO) Partners with Septerna to Develop Obesity and Diabetes Drugs - GuruFocus
Septerna Inc Azioni (SEPN) Dati Finanziari
Non sono disponibili dati finanziari per Septerna Inc (SEPN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):